aluates Reports

$ 0.0

Automative

Global Fragile X Syndrome Market Research Report 2024

Published Date: August 2024

Report Code: QYRE-Auto-29T6009

Global Fragile X Syndrome Market Insights Forecast to 2028

BUY CHAPTERS

Global Fragile X Syndrome Market Research Report 2024

Code: QYRE-Auto-29T6009

Report

August 2024

Pages:82

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Aelis Farma SAS

Alcobra

AMO Pharma Limited

Confluence Pharmaceuticals LLC

Eli Lilly and Company

F Hoffmann La Roche Ltd

Marinus Pharmaceuticals Inc

MI.TO. Technology S.r.L.

Neuren Pharmaceuticals Limited

Ovid Therapeutics Inc.

Sage Therapeutics Inc

Zynerba Pharmaceuticals, Inc.

Fragile X Syndrome Market

The global Fragile X Syndrome market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Fragile X Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Fragile X Syndrome is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Fragile X Syndrome in Clinic is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Fragile X Syndrome include Aelis Farma SAS, Alcobra Ltd, AMO Pharma Limited, Confluence Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Marinus Pharmaceuticals, Inc., MI.TO. Technology S.r.L. and Neuren Pharmaceuticals Limited, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Fragile X Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fragile X Syndrome.

Report Scope

The Fragile X Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Fragile X Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Fragile X Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Fragile X Syndrome Market Report

Report Metric	Details
Report Name	Fragile X Syndrome Market
Segment by Type	ACT-01 AMO-01 ANAVEX-273 AUT-00206 Bryostatin-1 Cannabidiol Others
Segment by Application	Clinic Hopital Research Center
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Aelis Farma SAS, Alcobra Ltd, AMO Pharma Limited, Confluence Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Marinus Pharmaceuticals, Inc., MI.TO. Technology S.r.L., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Inc., Zynerba Pharmaceuticals, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fragile X Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Fragile X Syndrome Market report?

Ans: The main players in the Fragile X Syndrome Market are Aelis Farma SAS, Alcobra Ltd, AMO Pharma Limited, Confluence Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Marinus Pharmaceuticals, Inc., MI.TO. Technology S.r.L., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Inc., Zynerba Pharmaceuticals, Inc.

What are the Application segmentation covered in the Fragile X Syndrome Market report?

Ans: The Applications covered in the Fragile X Syndrome Market report are Clinic, Hopital, Research Center

What are the Type segmentation covered in the Fragile X Syndrome Market report?

Ans: The Types covered in the Fragile X Syndrome Market report are ACT-01, AMO-01, ANAVEX-273, AUT-00206, Bryostatin-1, Cannabidiol, Others

Recommended Reports

Rare Disease Markets

Syndrome & Disorder Care

Fibromyalgia & Related

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Fragile X Syndrome Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 ACT-01

1.2.3 AMO-01

1.2.4 ANAVEX-273

1.2.5 AUT-00206

1.2.6 Bryostatin-1

1.2.7 Cannabidiol

1.2.8 Others

1.3 Market by Application

1.3.1 Global Fragile X Syndrome Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Clinic

1.3.3 Hopital

1.3.4 Research Center

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Fragile X Syndrome Market Perspective (2019-2030)

2.2 Fragile X Syndrome Growth Trends by Region

2.2.1 Global Fragile X Syndrome Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Fragile X Syndrome Historic Market Size by Region (2019-2024)

2.2.3 Fragile X Syndrome Forecasted Market Size by Region (2025-2030)

2.3 Fragile X Syndrome Market Dynamics

2.3.1 Fragile X Syndrome Industry Trends

2.3.2 Fragile X Syndrome Market Drivers

2.3.3 Fragile X Syndrome Market Challenges

2.3.4 Fragile X Syndrome Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Fragile X Syndrome Players by Revenue

3.1.1 Global Top Fragile X Syndrome Players by Revenue (2019-2024)

3.1.2 Global Fragile X Syndrome Revenue Market Share by Players (2019-2024)

3.2 Global Fragile X Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Fragile X Syndrome Revenue

3.4 Global Fragile X Syndrome Market Concentration Ratio

3.4.1 Global Fragile X Syndrome Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Fragile X Syndrome Revenue in 2023

3.5 Fragile X Syndrome Key Players Head office and Area Served

3.6 Key Players Fragile X Syndrome Product Solution and Service

3.7 Date of Enter into Fragile X Syndrome Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Fragile X Syndrome Breakdown Data by Type

4.1 Global Fragile X Syndrome Historic Market Size by Type (2019-2024)

4.2 Global Fragile X Syndrome Forecasted Market Size by Type (2025-2030)

5 Fragile X Syndrome Breakdown Data by Application

5.1 Global Fragile X Syndrome Historic Market Size by Application (2019-2024)

5.2 Global Fragile X Syndrome Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Fragile X Syndrome Market Size (2019-2030)

6.2 North America Fragile X Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Fragile X Syndrome Market Size by Country (2019-2024)

6.4 North America Fragile X Syndrome Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Fragile X Syndrome Market Size (2019-2030)

7.2 Europe Fragile X Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Fragile X Syndrome Market Size by Country (2019-2024)

7.4 Europe Fragile X Syndrome Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Fragile X Syndrome Market Size (2019-2030)

8.2 Asia-Pacific Fragile X Syndrome Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Fragile X Syndrome Market Size by Region (2019-2024)

8.4 Asia-Pacific Fragile X Syndrome Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Fragile X Syndrome Market Size (2019-2030)

9.2 Latin America Fragile X Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Fragile X Syndrome Market Size by Country (2019-2024)

9.4 Latin America Fragile X Syndrome Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Fragile X Syndrome Market Size (2019-2030)

10.2 Middle East & Africa Fragile X Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Fragile X Syndrome Market Size by Country (2019-2024)

10.4 Middle East & Africa Fragile X Syndrome Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Aelis Farma SAS

11.1.1 Aelis Farma SAS Company Detail

11.1.2 Aelis Farma SAS Business Overview

11.1.3 Aelis Farma SAS Fragile X Syndrome Introduction

11.1.4 Aelis Farma SAS Revenue in Fragile X Syndrome Business (2019-2024)

11.1.5 Aelis Farma SAS Recent Development

11.2 Alcobra Ltd

11.2.1 Alcobra Ltd Company Detail

11.2.2 Alcobra Ltd Business Overview

11.2.3 Alcobra Ltd Fragile X Syndrome Introduction

11.2.4 Alcobra Ltd Revenue in Fragile X Syndrome Business (2019-2024)

11.2.5 Alcobra Ltd Recent Development

11.3 AMO Pharma Limited

11.3.1 AMO Pharma Limited Company Detail

11.3.2 AMO Pharma Limited Business Overview

11.3.3 AMO Pharma Limited Fragile X Syndrome Introduction

11.3.4 AMO Pharma Limited Revenue in Fragile X Syndrome Business (2019-2024)

11.3.5 AMO Pharma Limited Recent Development

11.4 Confluence Pharmaceuticals LLC

11.4.1 Confluence Pharmaceuticals LLC Company Detail

11.4.2 Confluence Pharmaceuticals LLC Business Overview

11.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Introduction

11.4.4 Confluence Pharmaceuticals LLC Revenue in Fragile X Syndrome Business (2019-2024)

11.4.5 Confluence Pharmaceuticals LLC Recent Development

11.5 Eli Lilly and Company

11.5.1 Eli Lilly and Company Company Detail

11.5.2 Eli Lilly and Company Business Overview

11.5.3 Eli Lilly and Company Fragile X Syndrome Introduction

11.5.4 Eli Lilly and Company Revenue in Fragile X Syndrome Business (2019-2024)

11.5.5 Eli Lilly and Company Recent Development

11.6 F. Hoffmann-La Roche Ltd.

11.6.1 F. Hoffmann-La Roche Ltd. Company Detail

11.6.2 F. Hoffmann-La Roche Ltd. Business Overview

11.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Introduction

11.6.4 F. Hoffmann-La Roche Ltd. Revenue in Fragile X Syndrome Business (2019-2024)

11.6.5 F. Hoffmann-La Roche Ltd. Recent Development

11.7 Marinus Pharmaceuticals, Inc.

11.7.1 Marinus Pharmaceuticals, Inc. Company Detail

11.7.2 Marinus Pharmaceuticals, Inc. Business Overview

11.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Introduction

11.7.4 Marinus Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2019-2024)

11.7.5 Marinus Pharmaceuticals, Inc. Recent Development

11.8 MI.TO. Technology S.r.L.

11.8.1 MI.TO. Technology S.r.L. Company Detail

11.8.2 MI.TO. Technology S.r.L. Business Overview

11.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Introduction

11.8.4 MI.TO. Technology S.r.L. Revenue in Fragile X Syndrome Business (2019-2024)

11.8.5 MI.TO. Technology S.r.L. Recent Development

11.9 Neuren Pharmaceuticals Limited

11.9.1 Neuren Pharmaceuticals Limited Company Detail

11.9.2 Neuren Pharmaceuticals Limited Business Overview

11.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Introduction

11.9.4 Neuren Pharmaceuticals Limited Revenue in Fragile X Syndrome Business (2019-2024)

11.9.5 Neuren Pharmaceuticals Limited Recent Development

11.10 Ovid Therapeutics Inc.

11.10.1 Ovid Therapeutics Inc. Company Detail

11.10.2 Ovid Therapeutics Inc. Business Overview

11.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Introduction

11.10.4 Ovid Therapeutics Inc. Revenue in Fragile X Syndrome Business (2019-2024)

11.10.5 Ovid Therapeutics Inc. Recent Development

11.11 Sage Therapeutics, Inc.

11.11.1 Sage Therapeutics, Inc. Company Detail

11.11.2 Sage Therapeutics, Inc. Business Overview

11.11.3 Sage Therapeutics, Inc. Fragile X Syndrome Introduction

11.11.4 Sage Therapeutics, Inc. Revenue in Fragile X Syndrome Business (2019-2024)

11.11.5 Sage Therapeutics, Inc. Recent Development

11.12 Zynerba Pharmaceuticals, Inc.

11.12.1 Zynerba Pharmaceuticals, Inc. Company Detail

11.12.2 Zynerba Pharmaceuticals, Inc. Business Overview

11.12.3 Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Introduction

11.12.4 Zynerba Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2019-2024)

11.12.5 Zynerba Pharmaceuticals, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Aelis Farma SAS

Alcobra

AMO Pharma Limited

Confluence Pharmaceuticals LLC

Eli Lilly and Company

F Hoffmann La Roche Ltd

Marinus Pharmaceuticals Inc

MI.TO. Technology S.r.L.

Neuren Pharmaceuticals Limited

Ovid Therapeutics Inc.

Sage Therapeutics Inc

Zynerba Pharmaceuticals, Inc.

List of Tables

Table 1. Global Fragile X Syndrome Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of ACT-01

Table 3. Key Players of AMO-01

Table 4. Key Players of ANAVEX-273

Table 5. Key Players of AUT-00206

Table 6. Key Players of Bryostatin-1

Table 7. Key Players of Cannabidiol

Table 8. Key Players of Others

Table 9. Global Fragile X Syndrome Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 10. Global Fragile X Syndrome Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 11. Global Fragile X Syndrome Market Size by Region (2019-2024) & (US$ Million)

Table 12. Global Fragile X Syndrome Market Share by Region (2019-2024)

Table 13. Global Fragile X Syndrome Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 14. Global Fragile X Syndrome Market Share by Region (2025-2030)

Table 15. Fragile X Syndrome Market Trends

Table 16. Fragile X Syndrome Market Drivers

Table 17. Fragile X Syndrome Market Challenges

Table 18. Fragile X Syndrome Market Restraints

Table 19. Global Fragile X Syndrome Revenue by Players (2019-2024) & (US$ Million)

Table 20. Global Fragile X Syndrome Market Share by Players (2019-2024)

Table 21. Global Top Fragile X Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fragile X Syndrome as of 2023)

Table 22. Ranking of Global Top Fragile X Syndrome Companies by Revenue (US$ Million) in 2023

Table 23. Global 5 Largest Players Market Share by Fragile X Syndrome Revenue (CR5 and HHI) & (2019-2024)

Table 24. Key Players Headquarters and Area Served

Table 25. Key Players Fragile X Syndrome Product Solution and Service

Table 26. Date of Enter into Fragile X Syndrome Market

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Fragile X Syndrome Market Size by Type (2019-2024) & (US$ Million)

Table 29. Global Fragile X Syndrome Revenue Market Share by Type (2019-2024)

Table 30. Global Fragile X Syndrome Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 31. Global Fragile X Syndrome Revenue Market Share by Type (2025-2030)

Table 32. Global Fragile X Syndrome Market Size by Application (2019-2024) & (US$ Million)

Table 33. Global Fragile X Syndrome Revenue Market Share by Application (2019-2024)

Table 34. Global Fragile X Syndrome Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 35. Global Fragile X Syndrome Revenue Market Share by Application (2025-2030)

Table 36. North America Fragile X Syndrome Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. North America Fragile X Syndrome Market Size by Country (2019-2024) & (US$ Million)

Table 38. North America Fragile X Syndrome Market Size by Country (2025-2030) & (US$ Million)

Table 39. Europe Fragile X Syndrome Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 40. Europe Fragile X Syndrome Market Size by Country (2019-2024) & (US$ Million)

Table 41. Europe Fragile X Syndrome Market Size by Country (2025-2030) & (US$ Million)

Table 42. Asia-Pacific Fragile X Syndrome Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 43. Asia-Pacific Fragile X Syndrome Market Size by Region (2019-2024) & (US$ Million)

Table 44. Asia-Pacific Fragile X Syndrome Market Size by Region (2025-2030) & (US$ Million)

Table 45. Latin America Fragile X Syndrome Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Latin America Fragile X Syndrome Market Size by Country (2019-2024) & (US$ Million)

Table 47. Latin America Fragile X Syndrome Market Size by Country (2025-2030) & (US$ Million)

Table 48. Middle East & Africa Fragile X Syndrome Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 49. Middle East & Africa Fragile X Syndrome Market Size by Country (2019-2024) & (US$ Million)

Table 50. Middle East & Africa Fragile X Syndrome Market Size by Country (2025-2030) & (US$ Million)

Table 51. Aelis Farma SAS Company Detail

Table 52. Aelis Farma SAS Business Overview

Table 53. Aelis Farma SAS Fragile X Syndrome Product

Table 54. Aelis Farma SAS Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 55. Aelis Farma SAS Recent Development

Table 56. Alcobra Ltd Company Detail

Table 57. Alcobra Ltd Business Overview

Table 58. Alcobra Ltd Fragile X Syndrome Product

Table 59. Alcobra Ltd Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 60. Alcobra Ltd Recent Development

Table 61. AMO Pharma Limited Company Detail

Table 62. AMO Pharma Limited Business Overview

Table 63. AMO Pharma Limited Fragile X Syndrome Product

Table 64. AMO Pharma Limited Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 65. AMO Pharma Limited Recent Development

Table 66. Confluence Pharmaceuticals LLC Company Detail

Table 67. Confluence Pharmaceuticals LLC Business Overview

Table 68. Confluence Pharmaceuticals LLC Fragile X Syndrome Product

Table 69. Confluence Pharmaceuticals LLC Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 70. Confluence Pharmaceuticals LLC Recent Development

Table 71. Eli Lilly and Company Company Detail

Table 72. Eli Lilly and Company Business Overview

Table 73. Eli Lilly and Company Fragile X Syndrome Product

Table 74. Eli Lilly and Company Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 75. Eli Lilly and Company Recent Development

Table 76. F. Hoffmann-La Roche Ltd. Company Detail

Table 77. F. Hoffmann-La Roche Ltd. Business Overview

Table 78. F. Hoffmann-La Roche Ltd. Fragile X Syndrome Product

Table 79. F. Hoffmann-La Roche Ltd. Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 80. F. Hoffmann-La Roche Ltd. Recent Development

Table 81. Marinus Pharmaceuticals, Inc. Company Detail

Table 82. Marinus Pharmaceuticals, Inc. Business Overview

Table 83. Marinus Pharmaceuticals, Inc. Fragile X Syndrome Product

Table 84. Marinus Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 85. Marinus Pharmaceuticals, Inc. Recent Development

Table 86. MI.TO. Technology S.r.L. Company Detail

Table 87. MI.TO. Technology S.r.L. Business Overview

Table 88. MI.TO. Technology S.r.L. Fragile X Syndrome Product

Table 89. MI.TO. Technology S.r.L. Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 90. MI.TO. Technology S.r.L. Recent Development

Table 91. Neuren Pharmaceuticals Limited Company Detail

Table 92. Neuren Pharmaceuticals Limited Business Overview

Table 93. Neuren Pharmaceuticals Limited Fragile X Syndrome Product

Table 94. Neuren Pharmaceuticals Limited Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 95. Neuren Pharmaceuticals Limited Recent Development

Table 96. Ovid Therapeutics Inc. Company Detail

Table 97. Ovid Therapeutics Inc. Business Overview

Table 98. Ovid Therapeutics Inc. Fragile X Syndrome Product

Table 99. Ovid Therapeutics Inc. Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 100. Ovid Therapeutics Inc. Recent Development

Table 101. Sage Therapeutics, Inc. Company Detail

Table 102. Sage Therapeutics, Inc. Business Overview

Table 103. Sage Therapeutics, Inc. Fragile X Syndrome Product

Table 104. Sage Therapeutics, Inc. Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 105. Sage Therapeutics, Inc. Recent Development

Table 106. Zynerba Pharmaceuticals, Inc. Company Detail

Table 107. Zynerba Pharmaceuticals, Inc. Business Overview

Table 108. Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Product

Table 109. Zynerba Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2019-2024) & (US$ Million)

Table 110. Zynerba Pharmaceuticals, Inc. Recent Development

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Fragile X Syndrome Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Fragile X Syndrome Market Share by Type: 2023 VS 2030

Figure 3. ACT-01 Features

Figure 4. AMO-01 Features

Figure 5. ANAVEX-273 Features

Figure 6. AUT-00206 Features

Figure 7. Bryostatin-1 Features

Figure 8. Cannabidiol Features

Figure 9. Others Features

Figure 10. Global Fragile X Syndrome Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 11. Global Fragile X Syndrome Market Share by Application: 2023 VS 2030

Figure 12. Clinic Case Studies

Figure 13. Hopital Case Studies

Figure 14. Research Center Case Studies

Figure 15. Fragile X Syndrome Report Years Considered

Figure 16. Global Fragile X Syndrome Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global Fragile X Syndrome Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Fragile X Syndrome Market Share by Region: 2023 VS 2030

Figure 19. Global Fragile X Syndrome Market Share by Players in 2023

Figure 20. Global Top Fragile X Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fragile X Syndrome as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by Fragile X Syndrome Revenue in 2023

Figure 22. North America Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America Fragile X Syndrome Market Share by Country (2019-2030)

Figure 24. United States Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Canada Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Fragile X Syndrome Market Share by Country (2019-2030)

Figure 28. Germany Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Fragile X Syndrome Market Share by Region (2019-2030)

Figure 36. China Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Japan Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. South Korea Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. India Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Australia Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Fragile X Syndrome Market Share by Country (2019-2030)

Figure 44. Mexico Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Brazil Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Fragile X Syndrome Market Share by Country (2019-2030)

Figure 48. Turkey Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Fragile X Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Aelis Farma SAS Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 51. Alcobra Ltd Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 52. AMO Pharma Limited Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 53. Confluence Pharmaceuticals LLC Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 54. Eli Lilly and Company Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 55. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 56. Marinus Pharmaceuticals, Inc. Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 57. MI.TO. Technology S.r.L. Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 58. Neuren Pharmaceuticals Limited Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 59. Ovid Therapeutics Inc. Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 60. Sage Therapeutics, Inc. Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 61. Zynerba Pharmaceuticals, Inc. Revenue Growth Rate in Fragile X Syndrome Business (2019-2024)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Triple X Syndrome Management Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Rare Disease Genetic Testing Market

Global X protein Market Research Report 2024

Global Rare Disease Therapeutic Market Research Report 2024

Global Fibroblast Growth Factors FGF Market Research Report 2025

Leigh Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Restless Legs Syndrome Market Research Report 2025

Global Genetic Disorders Drug Market Research Report 2024

Global Reproductive Genetics Market Research Report 2024

Global Genetic Disease Diagnostic Market Research Report 2025

Global Pigmentation Disorder Product Market Research Report 2025

Global Special Needs Toys Market Research Report 2024

Global Fibroin Market Research Report 2024

Global Cognitive Decline Market Research Report 2024

Global Prenatal Genetic Screening Services Market Research Report 2025

Global Frac Tanks Market Research Report 2025

Global Pyridoxine Market Research Report 2024

Global Restless Legs Syndrome Treatment Market Research Report 2025

Global Hypopigmentation Disorder Product Market Research Report 2025

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Chronic Pain Medical Devices Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-0I20198

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Disposable Insulin Pen Needle Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-33W11115

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32E19705

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions